Biovica, a biotech company focused on improving cancer diagnostics and providing assays for better prediction of outcome and monitoring of cancer therapies, has entered into a research collaboration with the Dana-Farber Cancer Institute, Boston, MA.
Biovica’s DiviTum™ technology that measures cell proliferation rate with high sensitivity & precision will be used in a clinical trial to analyze blood (serum) from patients with non-small cell lung cancer. In the study, specific cell-cycle dependent drugs will be evaluated. The aim is to provide evidence that DiviTum™ can predict and monitor efficacy before and on treatment.
“We appreciate this opportunity to test DiviTum™ in a clinical study and assess its potential as a serum biomarker. We look forward to results.”, says the Principal Investigator in the study, Dr Geoffrey Shapiro, M.D, Ph.D, Director, Early Drug Development Center, Dana-Farber Cancer Institute.
Anders Rylander, CEO Biovica: “We are very pleased to collaborate with the Dana-Farber Cancer Institute in a clinical trial. It’s a fantastic opportunity for Biovica to include DiviTum™ in a highly relevant clinical study with a world renown and first class cancer institute”.
Facts about Dana-Farber Cancer Institute
Since its founding in 1947, Dana-Farber Cancer Institute in Boston, Massachusetts has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow’s cures through cutting-edge research. Read more about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities at www.dana-farber.org